Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: The 3-city study

Archives of Internal Medicine

Volumn 169, Issue 14, 2009, Pages 1317-1324

  Carrière, Isabelle ^a   Fourrier Reglat, Annie ^a   Dartigues, Jean François ^a   Rouaud, Olivier ^b   Pasquier, Florence ^c   Ritchie, Karen ^a   Ancelin, Marie Laure ^a,d  

^a INSERM   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d Montpellier 1 University   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; APOLIPOPROTEIN E; CARDIOVASCULAR AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT; SPASMOLYTIC AGENT;

AGED; ANTICHOLINERGIC EFFECT; ARTICLE; ASTHMA; COGNITIVE DEFECT; COHORT ANALYSIS; CONFIDENCE INTERVAL; DEMENTIA; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENETIC RISK; GERIATRIC PATIENT; HAZARD RATIO; HORMONAL THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; CHOLINERGIC ANTAGONISTS; COGNITION; DEMENTIA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LONGITUDINAL STUDIES; MALE; SEX FACTORS;

EID: 67749103704     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2009.229     Document Type: Article

References (47)

1. Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15(1):15-28.
2. Hilmer SN, McLachlan AJ, Le Couteur DG. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol. 2007;21(3):217-230.
3. Mulsant BH, Pollock BG, Kirshner M, Shen C, Dodge H, Ganguli M. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry. 2003;60(2):198-203.
4. Lechevallier-Michel N, Molimard M, Dartigues JF, Fabrigoule C, Fourrier-Reglat A. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study. Br J Clin Pharmacol. 2005;59(2):143-151.
5. Cao YJ, Mager DE, Simonsick EM, et al. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther. 2008;83(3):422-429.
6. Cancelli I, Gigli GL, Piani A, et al. Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: a population-based study. J Clin Psychopharmacol. 2008;28(6):654-659.
7. Nebes RD, Pollock BG, Meltzer CC, et al. Serum anticholinergic activity, white matter hyperintensities, and cognitive performance. Neurology. 2005;65(9):1487-1489.
8. Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167(8):781-787.
9. Bottiggi KA, Salazar JC, Yu L, et al. Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry. 2006;14(11):980-984.
10. Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ. 2006;332(7539):455-459.
11. Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc. 2008;56(12):2203-2210.
12. Pomara N, Belzer K, Hernando R, De La Pena C, Sidtis JJ. Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly. Am J Geriatr Psychiatry. 2008;16(2):116-124.
13. Pomara N, Willoughby LM, Wesnes K, Sidtis JJ. Increased anticholinergic challenge-induced memory impairment associated with the APOE-epsilon4 allele in the elderly: a controlled pilot study. Neuropsychopharmacology. 2004;29(2):403-409.
14. Artero S, Ancelin ML, Portet F, et al. Risk profiles for mild cognitive impairment and progression to dementia are gender specific. J Neurol Neurosurg Psychiatry. 2008;79(9):979-984.
15. Dumas J, Hancur-Bucci C, Naylor M, Sites C, Newhouse P. Estrogen treatment effects on anticholinergic-induced cognitive dysfunction in normal postmenopausal women. Neuropsychopharmacology. 2006;31(9):2065-2078.
16. Dumas J, Hancur-Bucci C, Naylor M, Sites C, Newhouse P. Estradiol interacts with the cholinergic system to affect verbal memory in postmenopausal women: evidence for the critical period hypothesis. Horm Behav. 2008;53(1):159-169.
17. 3C Study Group. Vascular factors and risk of dementia: Design of the three city study and baseline characteristics of the study population. Neuroepidemiology. 2003;22(6):316-325.
18. Isaacs B, Kennie AT. The Set test as an aid to the detection of dementia in old people. Br J Psychiatry. 1973;123(575):467-470.
19. Benton A. Manuel pour l'Application du Test de Rétention Visuelle: Applications Cliniques et Expérimentales. Paris, France: Centre de Psychologie Appliquée; 1965.
20. Reitan R. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills. 1958;8:271-276.
21. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
22. Ritchie K, Carriere I, de Mendonca A, et al. The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology. 2007;69(6):536-545.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association; 1994.
24. World Health Organization. World Health Organization Collaborating Centre for Drug Statistics Methodology: Guidelines for ATC Classification and DDD Assignment. Oslo, Norway: WHO; 2000.
25. Thériaque Web site. http://www.theriaque.org. Accessed January 15, 2009.
26. Banque de Données Automatisée sur les Médicaments (BIAM) Web site. http://www2.biam2.org. Accessed January 15, 2009.
27. VIDAL Web site. http://www.vidal.fr. Accessed January 15, 2009.
28. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385-401.
29. Commenges D, Letenneur L, Joly P, Alioum A, Dartigues JF. Modelling age-specific risk: application to dementia. Stat Med. 1998;17(17):1973-1988.
30. Hejl A, Hogh P, Waldemar G. Potentially reversible conditions in 1000 consecutive memory clinic patients. J Neurol Neurosurg Psychiatry. 2002;73(4):390-394.
31. Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology. 2001;56(1):37-42.
32. Fernaeus SE, Almkvist O. Word production: dissociation of two retrieval modes of semantic memory across time. J Clin Exp Neuropsychol. 1998;20(2):137-143.
33. Flicker C, Ferris SH, Serby M. Hypersensitivity to scopolamine in the elderly. Psychopharmacology (Berl). 1992;107(2-3):437-441.
34. Molchan SE, Martinez RA, Hill JL, et al. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev. 1992;17(3):215-226.
35. Ray PG, Meador KJ, Loring DW, Zamrini EW, Yang XH, Buccafusco JJ. Central anticholinergic hypersensitivity in aging. J Geriatr Psychiatry Neurol. 1992;5(2):72-77.
36. Bowie MW, Slattum PW. Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother. 2007;5(3):263-303.
37. Ancelin ML, Ritchie K. Lifelong endocrine fluctuations and related cognitive disorders. Curr Pharm Des. 2005;11(32):4229-4252.
38. Fleisher A, Grundman M, Jack CR Jr, et al; Alzheimer's Disease Cooperative Study. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol. 2005;62(6):953-957.
39. Yaffe K, Haan M, Byers A, Tangen C, Kuller L. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology. 2000;54(10):1949-1954.
40. Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol. 2003;54(2):235-238.
41. Fisher A, Pittel Z, Haring R, et al. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy. J Mol Neurosci. 2003;20(3):349-356.
42. Rudd KM, Raehl CL, Bond CA, Abbruscato TJ, Stenhouse AC. Methods for assessing drug-related anticholinergic activity. Pharmacotherapy. 2005;25(11):1592-1601.
43. Noize P, Bazin F, Dufouil C, et al. Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study. Pharmacoepidemiol Drug Saf. 2009;18(4):310-319.
44. Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315(7115):1096-1099.
45. Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005;165(7):808-813.
46. Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. Am J Geriatr Psychiatry. 2003;11(4):458-461.
47. Cancelli I, Valentinis L, Merlino G, Valente M, Gigli GL. Drugs with anticholinergic properties as a risk factor for psychosis in patients affected by Alzheimer's disease. Clin Pharmacol Ther. 2008;84(1):63-68.